Clinical Trials
143 trialsA First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors
Kupando GmbH
INTerpath-007
Merck Sharp & Dohme LLC
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Pfizer
Agni-01
Obsidian Therapeutics, Inc.
ELEPHAS-02
Elephas
ARTACUS
Replimune, Inc.
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
Regeneron Pharmaceuticals
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
Incyte Corporation
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
Iovance Biotherapeutics, Inc.
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
TuHURA Biosciences, Inc.
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
Pfizer
Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia (DaRT)
Alpha Tau Medical LTD.
Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC
Alpha Tau Medical LTD.
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Iovance Biotherapeutics, Inc.
CivaDerm(TM) Surface Therapy Pilot Study
CivaTech Oncology
Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors
Immorna Biotherapeutics, Inc.
Virtual Sun Safe Workplaces Ph II (SSW Works)
Klein Buendel, Inc.
ADVICE
Filamon LTD
PORTSIDE
Pfizer
A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India
Bristol-Myers Squibb
ANCHOR
Ankyra Therapeutics, Inc
COLUMBUS
Pfizer
Using an Artificial Intelligence Medical Device to Help Primary Care Practitioners Identify and Manage Skin Conditions (Tumor, Inflammatory, and Infectious Diseases) in Adult Patients at Pozuelo and Majadahonda Health Centers
AI Labs Group S.L
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
Regeneron Pharmaceuticals
ELEPHAS-05
Elephas
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
ON-5001
OncoNano Medicine, Inc.
Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal and Superficial Soft Tissue Neoplasia (DaRT)
Alpha Tau Medical LTD.
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.
Alpha Tau Medical LTD.
Retreatment With Intratumoral Diffusing Alpha Radiation Emitters
Alpha Tau Medical LTD.
A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma
Alpha Tau Medical LTD.
DaRT
Alpha Tau Medical LTD.
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
Skin Cancer
Nuvana Healthcare LTD
COMBI-i
Novartis
DELFI-L101
Delfi Diagnostics Inc.
ABILITY-1
Medicenna Therapeutics, Inc.
How Consistent is the Output of DERM, When Used to Assess Images of Potentially Cancerous Skin Lesions.
Skin Analytics Limited
Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma
Verrica Pharmaceuticals Inc.
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
DermaFlow
HJN Sverige AB/Neko Health
Spectrum1
HJN Sverige AB/Neko Health
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
Regeneron Pharmaceuticals
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
RAPTOR
Turnstone Biologics, Corp.
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
CheckMate-6GE
Bristol-Myers Squibb
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia
Alpha Tau Medical LTD.
DermScan
Barco NV